Field Trial Program News Today

Firms. Its not really an earnings beat its a subscriber beat thats what investors and analysts that have covered it correctly have been focused on because the more they add net subs around the world and the u. S. , the more the future profits can grow and nobody is really worried about profitability right now. They havent been for a long time thats been the incorrect lens to view this company the correct lens has been sub growth and the ability to raise prices they have pulled off both. Keep in ...

Jon Riley, Bayer Crop Science USDA’s approval for nonregulated status of Bayer’s ThryvOn Technology brings the biotech trait one step closer to commercial launch. First cotton biotech trait providing protection from thrips and tarnished plant bugs moves to next stage in development. Could soon be available to U.S. growers. The USDA has approved Bayer’s petition for nonregulated status of ThryvOn Technology, bringing it one step closer to commercial launch. ...